etrasimod vs Ponesimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
etrasimod · Velsipity
Marketed by Pfizer and partners
NCT03945188 · Phase 3 · completed
Randomized 2:1, double-blind, placebo-controlled, adequately powered (n=433) phase 3 trial with a hard clinical/endoscopic composite primary endpoint (clinical remission via modified Mayo score incorporating centrally-read endoscopy), and both co-primary endpoint comparisons reached statistical significance in the favorable direction (p<0.001), satisfying the 'strong' definition.
Next expected readout: June 2027 · NCT07782242 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Clinical Remission at Week 12; Percentage of Participants Achieving Clinical Remission at Week 52: Percentage of Participants Achieving Clinical Remission at Week 12 (At Week 12): Etrasimod 2 mg 27.0% vs Placebo 7.4%; p=<0.001 (Etrasimod 2 mg vs Placebo) (met)
Result source: NCT03945188
Ponesimod
Marketed by Vanda Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2029 · NCT07686081 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | etrasimod | Ponesimod |
|---|---|---|
| Clinical remission (induction) | 27% vs 7.4%+19.6 vs placeboNCT039451886 other results
| —Trial running · NCT07686081 |
| Clinical remission (maintenance) | 32.1% vs 6.7%+25.4 vs placeboNCT039451883 other results
| —Trial running · NCT07686081 |
| Clinical response (induction) | 62.4% vs 34.1%+28.3 vs placeboNCT039451886 other results
| —Trial running · NCT07686081 |
| Endoscopic improvement (induction) | 35% vs 14.1%+20.9 vs placeboNCT039451886 other results
| —Trial running · NCT07686081 |
| Corticosteroid-free remission (maintenance) | 32.1% vs 6.7%+25.4 vs placeboNCT039451886 other results
| —Trial running · NCT07686081 |
Clinical remission (induction)
- etrasimod
- 27% vs 7.4%+19.6 vs placeboNCT03945188
6 other results
- 24.8% vs 15.2% NCT03996369
- 26.3% vs 0% NCT05061446
- 6.7% vs 0% NCT05061446
- 33% vs 8.1% NCT02447302
- 16% vs 8.1% NCT02447302
- 28.3% vs 11.7% NCT04607837
- Ponesimod
- —Trial running · NCT07686081
Clinical remission (maintenance)
- etrasimod
- 32.1% vs 6.7%+25.4 vs placeboNCT03945188
3 other results
- 25% vs 7.1% NCT04706793
- 49.1% vs 17.4% NCT03945188
- 26% vs 18.3% NCT04607837
- Ponesimod
- —Trial running · NCT07686081
Clinical response (induction)
- etrasimod
- 62.4% vs 34.1%+28.3 vs placeboNCT03945188
6 other results
- 62.2% vs 41.1% NCT03996369
- 50.6% vs 32.5% NCT02447302
- 43.7% vs 32.5% NCT02447302
- 55.9% vs 36.7% NCT04607837
- 52.6% vs 7.1% NCT05061446
- 33.3% vs 7.1% NCT05061446
- Ponesimod
- —Trial running · NCT07686081
Endoscopic improvement (induction)
- etrasimod
- 35% vs 14.1%+20.9 vs placeboNCT03945188
6 other results
- 30.6% vs 18.8% NCT03996369
- 41.8% vs 17.8% NCT02447302
- 22.5% vs 17.8% NCT02447302
- 44.1% vs 20% NCT04607837
- 26.3% vs 0% NCT05061446
- 6.7% vs 0% NCT05061446
- Ponesimod
- —Trial running · NCT07686081
Corticosteroid-free remission (maintenance)
- etrasimod
- 32.1% vs 6.7%+25.4 vs placeboNCT03945188
6 other results
- 31% vs 7.5% NCT03945188
- 25% vs 7.1% NCT04706793
- 25.2% vs 16.7% NCT04607837
- 25.2% vs 16.7% NCT04607837
- 16.2% vs 16.7% NCT04607837
- 30% vs 30% NCT04607837
- Ponesimod
- —Trial running · NCT07686081
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ponesimod: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. etrasimod: 4 of 4 rows · Ponesimod: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | etrasimod |
|---|---|
| Dropout rate | 44.3%2 mga NCT03945188 · Phase 3 · monotherapy show 8 more results10.5%2 mg NCT03996369 · Phase 3 · monotherapy 35.7%2 mg NCT04706793 · Phase 3 · monotherapy 37.4% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 5.9%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 17.9%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 8%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 9.6%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.5%2 mga NCT03945188 · Phase 3 · monotherapy show 8 more results3.8%2 mg NCT03996369 · Phase 3 · monotherapy —2 mg NCT04706793 · Phase 3 · monotherapy 5.2% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 0%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 4.5%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 6%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 7.7%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.9%2 mga NCT03945188 · Phase 3 · monotherapy show 8 more results2.5%2 mg NCT03996369 · Phase 3 · monotherapy 3.6%2 mg NCT04706793 · Phase 3 · monotherapy 6.5% NCT04607837 · Phase 2 · registry result, not featured evidence 0%2 mg NCT05061446 · Phase 2 · registry result, not featured evidence 0%1 mg NCT05061446 · Phase 2 · registry result, not featured evidence 6.3%2 mg NCT02536404 · Phase 2 · registry result, not featured evidence 0%2 mg NCT02447302 · Phase 2 · registry result, not featured evidence 5.8%1 mg NCT02447302 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 2 mga anaemia 8.3% (placebo 9.7%) headache 8.3% (placebo 4.9%) covid-19 6.6% (placebo 5.6%) NCT03945188 · Phase 3 · monotherapy show 8 more results2 mg anaemia 5.9% (placebo 6.9%) headache 4.6% (placebo 1.7%) nausea 4.2% (placebo 1.7%) NCT03996369 · Phase 3 · monotherapy 2 mg headache 14.3% (placebo 14.3%) malaise 10.7% (placebo 0%) pyrexia 10.7% (placebo 14.3%) NCT04706793 · Phase 3 · monotherapy colitis ulcerative 12.3% (placebo 10.1%) covid-19 9.7% (placebo 8.9%) alanine aminotransferase increased 8.4% (placebo 1.3%) NCT04607837 · Phase 2 · registry result, not featured evidence 2 mg alanine aminotransferase increased 5.3% (placebo 0%) back pain 5.3% (placebo 0%) blood creatine phosphokinase increased 5.3% (placebo 0%) NCT05061446 · Phase 2 · registry result, not featured evidence 1 mg stomatitis 11.8% (placebo 0%) anaemia 5.9% (placebo 0%) cataract 5.9% (placebo 0%) NCT05061446 · Phase 2 · registry result, not featured evidence 2 mg colitis ulcerative 14.3% (placebo 16.7%) anaemia 8.9% (placebo 0%) gamma-glutamyltransferase increased 8.9% (placebo 0%) NCT02536404 · Phase 2 · registry result, not featured evidence 2 mg anaemia 6% (placebo 3.7%) headache 6% (placebo 1.9%) colitis ulcerative 4% (placebo 1.9%) NCT02447302 · Phase 2 · registry result, not featured evidence 1 mg upper respiratory tract infection 7.7% (placebo 3.7%) colitis ulcerative 5.8% (placebo 1.9%) anaemia 3.8% (placebo 3.7%) NCT02447302 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
etrasimod
show 10 more results
show 9 more results
show 19 more results
show 5 more results
show 6 more results
show 2 more results
show 8 more results
show 4 more results
show 16 more results
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: etrasimod's landscape · Ponesimod's landscape